We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“This provides evidence that acoramidis is the only disease-modifying therapy that provides near-complete stabilization of TTR, improving clinical outcomes in both variant and wild-type ATTR-CM patients to an extent that is independently statistically significant in both subgroups.”
No takes yet. Share an insight, caveat, or question.
Maurer et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: